Search research articles
Contact Us
Filters
Showing results (171-180 of 192) with videos related to
Page
of 20
Sort By:
JAMA Oncology
|
February 9, 2023
Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial
Neil F Mariados, Peter F Orio, Zvi Schiffman, et al.
NEJM Evidence
|
February 6, 2024
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
Noel W Clarke, Andrew J Armstrong, Antoine Thiery-Vuillemin, et al.
Journal of Surgical Urology
|
November 23, 2022
Bacterial Interactions as Detected by Pooled Antibiotic Susceptibility Testing (P-AST) in Polymicrobial Urine Specimens
Annah Vollstedt, David Baunoch, Alan Wolfe, et al.
Cancer
|
August 7, 2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer
Tian Zhang, Michael R Harrison, Peter H O'Donnell, et al.
The Journal of Urology
|
August 9, 2024
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer
Neal Shore, Christopher Pieczonka, Sean Heron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 5, 2021
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation
Jonathan Tward, Lauren Lenz, Darl D Flake, et al.
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
European Urology Oncology
|
August 13, 2023
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial
Neal Shore, Mukaram Gazi, Christopher Pieczonka, et al.
JCO Oncology Practice
|
December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Neal Shore, Sarah M Nielsen, Edward D Esplin, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 192) with videos related to
Sort By:
Page
of 20
JAMA Oncology
|
February 9, 2023
Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial
Neil F Mariados, Peter F Orio, Zvi Schiffman, et al.
NEJM Evidence
|
February 6, 2024
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
Noel W Clarke, Andrew J Armstrong, Antoine Thiery-Vuillemin, et al.
Journal of Surgical Urology
|
November 23, 2022
Bacterial Interactions as Detected by Pooled Antibiotic Susceptibility Testing (P-AST) in Polymicrobial Urine Specimens
Annah Vollstedt, David Baunoch, Alan Wolfe, et al.
Cancer
|
August 7, 2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer
Tian Zhang, Michael R Harrison, Peter H O'Donnell, et al.
The Journal of Urology
|
August 9, 2024
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer
Neal Shore, Christopher Pieczonka, Sean Heron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 5, 2021
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation
Jonathan Tward, Lauren Lenz, Darl D Flake, et al.
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
European Urology Oncology
|
August 13, 2023
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial
Neal Shore, Mukaram Gazi, Christopher Pieczonka, et al.
JCO Oncology Practice
|
December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Neal Shore, Sarah M Nielsen, Edward D Esplin, et al.
Page
of 20